Whitehawk Therapeutics (WHWK) Net Cash Flow (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Net Cash Flow data on file, last reported at -$2.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 101.4% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$192.8 million, a 210.97% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, up 125.82% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$2.8 million, down from -$363000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for WHWK reached as high as $198.8 million in Q1 2025 and fell as low as -$107.0 million in Q3 2025.
• Historically, Net Cash Flow has averaged -$6.7 million across 5 years, with a median of -$5.9 million in 2023.
• Across the five-year window, Net Cash Flow sank 1753.98% in 2024 and surged 2283.08% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$95.8 million in 2022, then soared by 93.83% to -$5.9 million in 2023, then jumped by 68.44% to -$1.9 million in 2024, then jumped by 80.56% to -$363000.0 in 2025, then slumped by 665.29% to -$2.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$2.8 million in Q1 2026, -$363000.0 in Q4 2025, and -$107.0 million in Q3 2025.